Your browser doesn't support javascript.
loading
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Leere, Julius Simoni; Karmisholt, Jesper; Robaczyk, Maciej; Lykkeboe, Simon; Handberg, Aase; Steinkohl, Emilie; Brøndum Frøkjær, Jens; Vestergaard, Peter.
Afiliación
  • Leere JS; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: j.leere@rn.dk.
  • Karmisholt J; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Endocrinology, Aalborg University, Aalborg, Denmark.
  • Robaczyk M; Department of Endocrinology, Aalborg University, Aalborg, Denmark.
  • Lykkeboe S; Department of Clinical Biochemistry, Aalborg University, Aalborg, Denmark.
  • Handberg A; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Clinical Biochemistry, Aalborg University, Aalborg, Denmark.
  • Steinkohl E; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Radiology, Aalborg University, Aalborg, Denmark.
  • Brøndum Frøkjær J; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Radiology, Aalborg University, Aalborg, Denmark.
  • Vestergaard P; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Endocrinology, Aalborg University, Aalborg, Denmark; Steno Diabetes Center North Jutland, Aalborg, Denmark.
Lancet Diabetes Endocrinol ; 8(5): 407-417, 2020 05.
Article en En | MEDLINE | ID: mdl-32333877
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hiperparatiroidismo Primario / Cinacalcet / Denosumab Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hiperparatiroidismo Primario / Cinacalcet / Denosumab Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2020 Tipo del documento: Article